Illuminating the Evidence

Publication Summary

Rennie MY et al. Journal of Wound Care (2017).*



Point-of-care fluorescence imaging predicts the presence of pathogenic bacteria in wounds: a clinical study

Multi-site clinical trial finds that regions of red fluorescence are predictive of bacterial loads ≥10⁴ CFU/g in 100% of study wounds



Study Design

- The MolecuLight i:X Imaging Device illuminates wounds with 405 nm violet light, causing fluorescence signals to be emitted from tissues and bacteria. Most bacterial species appear red on MolecuLight i:X fluorescence images due to a red-fluorescent endogenous by-product of their metabolism, porphyrins.
- Multisite, prospective, single blind clinical trials (clinicaltrials.gov #NCT02682069, #NCT03091361) were conducted to determine the positive predictive value (PPV) of red fluorescence on MolecuLight i:X images for detecting bacteria in wounds.
- 60 lower limb chronic wounds (47 DFUs, 12 VLUs, 1 amputation) were imaged for bacterial fluorescence using the MolecuLight i:X Imaging Device. Regions positive for red fluorescence were discretely sampled using either biopsy or curettage, to correlate red fluorescence signals to bacterial presence.
- Biopsy samples were analysed via gold standard quantitative polymerase chain reaction (qPCR); curettage samples were analyzed via semi-quantitative culture analysis.



Key Results

The PPV of red fluorescence on MolecuLight i:X images was 100%, regardless of sampling method, analysis technique, or study site. No false positives were detected.




Figure 1: Total bacterial load quantified via 16S qPCR of biopsied regions of red fluorescence (n=30).




Figure 2: Bacterial load reported from culture analysis of curettaged regions of red fluorescence (n=30).

us.moleculight.com Continued >>>



Illuminating the Evidence (continued)



Key Results (continued)

- Total bacterial loads detected as red fluorescence in this study ranged from 10⁴ -10⁸ CFU/g. Total load was ≥ 10⁵ CFU/g in 87% of wounds accessed via qPCR. Culture analysis reported moderate growth or higher of at least one bacterial species in 93% of samples taken from regions of red fluorescence.
- The red fluorescence signal appeared very bright in some wounds, suggesting bacterial presence near the surface, while in other wounds blush red or pink suggested subsurface bacterial presence.
- Staphylococcus aureus was the most prevalent pathogen detected (23/60 wounds); Methicillin-Resistant Staphylococcus aureus (MRSA) was detected in 7/60 wounds. Other species detected included Enterobacter cloacae, Proteus mirabilis, Klebsiella pneumonia, and Citrobacter koseri.






Figure 3: Culture analysis of a curettage sample taken from the indicated region of red fluorescence (white arrow) in this diabetic foot ulcer reported moderate growth of MRSA and light growth of mixed bacteria.



Conclusion

Fluorescence guided sampling (curettage or biopsy) in regions of red fluorescence on MolecuLight *i:X* images positively predicts the presence of pathogenic or opportunistic bacteria at loads of clinical concern (≥ 10⁴ CFU/g). The lack of false positives in this study suggests that fluorescence guidance, in combination with subsurface sampling techniques, could entirely eliminate the risk of false negative wound sampling. Real-time information on the presence and location of bacterial burden within or around wounds could influence treatment decisions at the point of care.



Study Citation

*Rennie MY, Lindvere-Teene L, Tapang K, and Linden R. Point-of-care fluorescence imaging predicts the presence of pathogenic bacteria in wounds: a clinical study. Journal of Wound Care, 2017. 26(8): p. 452-460.

©2019 MolecuLight® Inc. All Rights Reserved. PN 1530 Rev 1.0

The MolecuLight £XTM Imaging Device has received FDA De Novo clearance, please see https://us.moleculight.com/ for USA specific intended & indications for use. The MolecuLight £XTM Imaging Device is approved by Health Canada (Medical License #95784) and has CE marking (Certificate #G1160292355002) for sale in Canada and the European Union. MolecuLight® is a Registered Trademark in the US, Canada, and the EU.

